Home | Welcome to Contract Pharma   
Last Updated Tuesday, June 2 2015

Print

Search Results for 'Financial Report: Sanofi'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published April 30, 2015
Genzyme sales up 31% in the quarter Read More »
Published February 5, 2015
Revenues up 7% in the quarter Read More »
Published October 28, 2014
Revenue up 4% in the quarter Read More »
Published August 8, 2014
Pharma sales up 7% in the quarter Read More »
Published April 29, 2014
Exchange rates hurt results Read More »
Published October 30, 2013
Product sales up for the first time in five quarters Read More »
Published August 1, 2013
Generic competition, Brazil issue impact results Read More »
Published May 2, 2013
Generic competition continues to hurt revenues Read More »
Published February 7, 2013
Revenues up 3% in the quarter, earnings hurt by generics Read More »
Published October 25, 2012
Genzyme revenues staunch patent losses Read More »
Published July 26, 2012
Loss of $205 million to generic competition in the quarter Read More »
Published February 8, 2012
Genzyme revenues, growth offset generic impact on flagship products Read More »
Published November 3, 2011
Earnings down due to generic competition Read More »
Published July 28, 2011
Generic competition hits Lovenox and Taxotere, Genzyme sales up 16% Read More »
Published April 28, 2011
Lantus sales were up 13% to $1.3 billion in the quarter. Read More »
Published February 10, 2010
Pharmaceutical sales were $9.0 billion (+3%) in 4Q09 and $37.0 billion (+4%) for FY09. Read More »
Published July 29, 2009
Pharmaceutical sales were up 7% to $9.4 billion. Read More »
Published April 29, 2009
Pharmaceutical sales were $8.6 billion (-1%). Lovenox sales were $1.0 billion (+1%). Read More »
Published February 11, 2009
Pharmaceutical sales were up 3% in the quarter and for the year to $9.1 billion and $35.1 billion, respectively. Lovenox sales were $1.1 billion in the quarter (+8%) and $3.9 billion for the year (+11%). Read More »
Published November 1, 2006
Sanofi-Aventis 3Q 3Q Revenues: $8.8 billion (-1%) 3Q Earnings: $1.5 billion YTD Revenues: $26.7 billion (+3%) YTD Earnings: $4.4 billion (+100%) Comments: 3Q net sales for the pharmaceuticals business were hit hard by the introduction… Read More »
Published February 24, 2006
Sanofi-Aventis 4Q Revenues: $8.3 billion (+7%) 4Q Earnings: $1.7 billion (+21%) FY Revenues: $32.5 billion (+8%) FY Earnings: $7.6 billion (+26%) Comments: R&D expenses were up 6.6% to $1.4 billion in the quarter and up 2% to… Read More »
Genzyme sales boost results Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On